We believe that this study applying the novel Bayes decision rule is the first to report the RFS significance of the combination of CD4+ and FOXP3+ T-cell densities identified by IHC in T3/T4a stage II CRC patients. This evidence concerns the gene CD4 and colorectal carcinoma.